Inhibitor Theraptics (INTI) Net Income by Year
Inhibitor Theraptics Inc reported a net loss of $3.3M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $3.3M net loss. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Inhibitor Theraptics Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
INTI Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
INTI Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Inhibitor Theraptics Inc financials
Frequently Asked Questions
Inhibitor Theraptics Inc reported a net loss of $3.3M in fiscal year 2025.
Inhibitor Theraptics Inc (INTI) reported a $3.3M net loss in fiscal year 2024 and a $3.3M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Inhibitor Theraptics Inc (INTI) reported a $3.3M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
Across the 14 fiscal years this page covers, Inhibitor Theraptics Inc (INTI) net income went from $186K in fiscal year 2012 to -$3.3M in fiscal year 2025.
Inhibitor Theraptics Inc (INTI) reported -$614K in net income in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Inhibitor Theraptics Inc (INTI) reported on that line in every period on record.